LGC's innovative SARS-CoV-2 Quality Solutions now includes S gene

In response to the critical need for accurate testing to combat the COVID-19 pandemic, LGC SeraCare continues to innovate and expand their novel AccuPlex™ SARS-CoV-2 Quality Solutions in support of improved diagnostic assay development and testing. The newly launched Version 2 Verification Panel, and Reference Material Kit, offer expanded genome coverage over the products first launched in March to now include the S gene region. As testing priorities shift from molecular to serological, LGC also plans to expand their product offering to antibody controls in continued support of public health efforts against COVID-19.

LGC’s proprietary AccuPlex technology mimics wild-type pathogenic viruses, but is safe, non-infectious, and replication deficient. These materials serve as true, full-process, quality control solutions that challenge the entire PCR test procedure, making them the preferred alternative to infectious materials. Together, the AccuPlex SARS-CoV-2 Verification Panel and AccuPlex SARS-CoV-2 Reference Material Kit offer an ideal solution for clinical laboratories looking for a safe, effective tool to verify and monitor SARS-CoV-2 molecular assay performance.

Michael Sweatt, Executive Vice President, LGC SeraCare, stated, “AccuPlex technology offers an urgently needed tool supporting assay installation and verification, and daily performance monitoring, in support of a growing footprint of available testing laboratories, and to meet an ever-increasing testing demand. LGC is committed to providing quality measurement tools to support in vitro diagnostic assay developers and clinical laboratories to help ensure accurate and reliable patient test results.”